Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Deposition of TRIMBOW in Healthy, Asthmatic and COPD Subjects
NCT03795350Phase 1Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma and chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Intrapulmonary lung deposition. Started Jan 2019; status: terminated.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03795350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795350.